Administration of Virus-Specific Cytotoxic T-Lymphocytes

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

July 31, 2003

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions
Adenovirus Infection
Interventions
BIOLOGICAL

CTL administration

"Adenovirus specific T cells will be given by intravenous injection from day 30 post transplant.~One infusion of Adenovirus-specific CTL given to patients at risk for Adenoviral disease after matched or mismatched unrelated or matched or mismatched related donor stem cell transplant. Four dose levels will be explored. The lowest level will be 1x dose of 5x10e6cells/m2 and the highest will be 1x dose of 1.35x10e8/m2."

Trial Locations (3)

20894

National Institute of Health (NIH), Washington D.C.

77030

Texas Children's Hospital, Houston

The Methodist Hospital, Houston

All Listed Sponsors
collaborator

Center for Cell and Gene Therapy, Baylor College of Medicine

OTHER

collaborator

The Methodist Hospital Research Institute

OTHER

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Baylor College of Medicine

OTHER

NCT00590083 - Administration of Virus-Specific Cytotoxic T-Lymphocytes | Biotech Hunter | Biotech Hunter